Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Bipolar disorders informants

Drug treatment is a vital part of the management of bipolar disorder, both during episodes of depression or mania and as prophylaxis thereafter. Patients require explanation and education about the illness and about the treatments available, in order to be able to make informed choices and to avail themselves of the appropriate options fot treatment. [Pg.70]

Based on all information presented, create a care plan for this patient s bipolar disorder. Your plan should include (1) a statement of the drug-related needs and/or problems, (2) the goals of therapy, (3) a patient-specific therapeutic plan, and (4) a plan for follow-up to assess therapeutic response and adverse effects. [Pg.590]

Product information, dosing and administration, clinical use, and proposed mechanisms of action for agents used for bipolar disorder are shown in Table 69-7. [Pg.779]

Starting Treatment in Children. The importance of an accurate diagnosis confirmed by obtaining information from multiple sources cannot be overstated. The mainstay of treatment for ADHD, psychostimulants, are less helpful for the other disruptive behavior disorders of childhood and may worsen the course of bipolar disorder in patients misdiagnosed with ADHD. [Pg.249]

Carbamazepine is believed to be effective in BPD, though the data is far less robust than with valproic acid. It is prescribed at doses up to 1200mg/day. Like valproic acid, it can also canse birth defects and requires laboratory monitoring including serum levels. For more information on the use of carbamazepine, please refer to the discussion of bipolar disorder treatment in Chapter 3. [Pg.328]

The relative absence of systematic studies of bipolar patients under age 18 forces clinicians to extrapolate data from adult studies. There are four major types of studies that provide information on subjects with bipolar disorder double-blind, placebo-controlled studies of patients with acute mania prospective open-label studies of patients with bipolar disorder (which includes mania, hypomania, manic symptoms, or bipolar NOS, people at risk for mania because of their family history, and those with a history of mania who are not currently manic) case series and anecdotal reports. [Pg.488]

Chart reviews and open trials of outpatients with bipolar disorder and bipolar spectrum disorder have been published for 28 risperidone- and 23 olanzapine-treated treated children and adolescents (Frazier et ah, 1999 2001). Significant decreases in mania, depression, and aggression ratings occurred over the course of treatment however, other medications were also used simultaneously. Additional anecdotal information exists for olanzapine (Soutullo et ah, 1999 Chang and Ketter, 2000), quetiapine (Schaller and Behar, 1999), and clozapine (Fuchs, 1994). [Pg.491]

To our knowledge, there have been no reports of controlled clinical trials of valproate as a prophylactic agent in bipolar disorder. Results from a number of open trials suggest that perhaps half of patients treated with valproate experience prophylactic benefit (reviewed in Keck et al. 1992a]. A placebo-controlled, double-blind study of the efficacy of the divalproex form of valproate is under way and may provide additional information regarding the use of this drug in the maintenance therapy of bipolar disorder. [Pg.148]

Chapter /, Modem Psychopharmaceuticals, written by Dr Hossein Fatemi, and Chapter 5, Psychopharmaceuticals and the Treatment of Mental Disorders, provide succinct, up to date, and well-referenced information on how to use the major classes of psychotropic drugs. The latter chapter discusses in a frank and balanced manner the ambivalence towards the use of pharmacologic agents in mental disorders felt by some, and the limitations on the achievements of current drugs as ideal therapies for schizophrenia, bipolar disorder and major depression in particular. Clearly, much has been accomplished, but many needs, especially for prevention of relapse, removal of specific types of symptoms, and restoraton of work and social function, remain to be accomplished by drug and psychosocial therapies. [Pg.423]

Abstract G72 and G30 constitute a pair of primate-specific genes on complementary strands of human chromosomal 13q33. G72 is proposed to encode a protein that can activate D-amino acid oxidase (DAAO), therefore, named as D-aminoacid oxidase activator (DAOA) (Chumakov et al., 2002). This hypothesis about G72 and DAAO requires substantial further proof (see discussion later), and the neutral name G72 will be used here, although DAOA is widely used in the literature now. The G72/ G30 gene is, at this time, one of the best supported loci for both schizophrenia (SZ) and bipolar disorder (BD) by independent datasets (Craddock et al., 2006 Detera-Wadleigh and McMahon, 2006). Here, we will describe the discovery of gene complex G72/G30, association studies with SZ and BD with a meta-analysis, as well as brief information about the biology of G72/G30. [Pg.94]

The response to olanzapine in 150 consecutive patients has been assessed by reviewing their records (21). Patients with a moderate-to-marked response to olanzapine were more likely to be younger, to be female, and to have a diagnosis of bipolar disorder. No information on adverse effects was provided. [Pg.302]

In utilizing the collaborative model in the management of bipolar disorder, as well as depression, the psychotherapist supports the inherent coping skills of the patient, assesses progress and resistance, and tracks medication compliance. The psychotherapist can then inform the psychiatrist of any changes that have occurred and/or are required, and vice versa, thereby resulting in a more comprehensive and quality-driven level of care. [Pg.77]

Of course, waiting for patients to make their own decisions does not mean that the therapist or physician cannot voice an opinion. If the therapist knows that evidence-based literature suggests that the patients problem is best treated with medication (i.e., bipolar disorder or OCD), that information should be given to the patients and their families. The patients should have all the necessary information they need to make an informed decision. Family and friends will also influence a patient s ini-... [Pg.213]

Use with caution, observing for acfivafion of known or unknown bipolar disorder and/or suicidal Ideation, and sfrongly consider informing parenfs or guardian of this risk so they can help observe child or adolescent patients... [Pg.17]


See other pages where Bipolar disorders informants is mentioned: [Pg.602]    [Pg.603]    [Pg.1]    [Pg.895]    [Pg.7]    [Pg.59]    [Pg.249]    [Pg.327]    [Pg.328]    [Pg.339]    [Pg.346]    [Pg.484]    [Pg.487]    [Pg.488]    [Pg.488]    [Pg.716]    [Pg.135]    [Pg.152]    [Pg.203]    [Pg.665]    [Pg.60]    [Pg.157]    [Pg.260]    [Pg.261]    [Pg.230]    [Pg.246]   
See also in sourсe #XX -- [ Pg.405 ]




SEARCH



Bipolar disorder

© 2024 chempedia.info